Treating MDR TB requires the use of second-line drugs, which are less effective, more toxic, and require longer treatment durations than first-line drugs. These include drugs like fluoroquinolones and injectables such as amikacin or capreomycin. The treatment can last up to 24 months, compared to the 6 to 9 months for drug-susceptible TB. This prolonged treatment increases the risk of adverse drug reactions and toxicity.
